BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Delangre E, Oppliger E, Berkcan S, Gjorgjieva M, Correia de Sousa M, Foti M. S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. IJMS 2022;23:11030. [DOI: 10.3390/ijms231911030] [Reference Citation Analysis]
2 Costante F, Airola C, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows. World J Gastrointest Oncol 2022; 14(9): 1622-1636 [DOI: 10.4251/wjgo.v14.i9.1622] [Reference Citation Analysis]
3 Zhao X, Yin S, Shi J, Zheng M, He C, Meng H, Han Y, Chen J, Han J, Yuan Z, Wang Y. The association between several autophagy-related genes and their prognostic values in hepatocellular carcinoma: a study on the foundation of TCGA, GEPIA and HPA databases. Mol Biol Rep 2022. [PMID: 36097121 DOI: 10.1007/s11033-022-07426-w] [Reference Citation Analysis]
4 Yu S, Wang J, Zheng H, Wang R, Johnson N, Li T, Li P, Lin J, Li Y, Yan J, Zhang Y, Zhu Z, Ding X. Pathogenesis from Inflammation to Cancer in NASH-Derived HCC. J Hepatocell Carcinoma 2022;9:855-67. [PMID: 36051860 DOI: 10.2147/JHC.S377768] [Reference Citation Analysis]
5 Guan X, Chen Y, Xu H. New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum. European Journal of Radiology 2022;154:110450. [DOI: 10.1016/j.ejrad.2022.110450] [Reference Citation Analysis]
6 Chen L, Fan Z, Sun X, Qiu W, Mu W, Chai K, Cao Y, Wang G, Lv G. Examination on the risk factors of cholangiocarcinoma: A Mendelian randomization study. Front Pharmacol 2022;13:900424. [DOI: 10.3389/fphar.2022.900424] [Reference Citation Analysis]
7 Gairing SJ, Schleicher EM, Labenz C. Diabetes mellitus - risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis? Metab Brain Dis 2022. [PMID: 36001211 DOI: 10.1007/s11011-022-01068-4] [Reference Citation Analysis]
8 Guo W, Luo L, Meng Y, Chen W, Yu L, Zhang C, Qiu Z, Cao P. Luteolin alleviates methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by modulating host serum metabolome and gut microbiome. Front Nutr 2022;9:936237. [PMID: 35990349 DOI: 10.3389/fnut.2022.936237] [Reference Citation Analysis]
9 Nishio T, Ito T, Hata K, Taura K, Hatano E. Current status of liver transplantation for non‐B non‐C liver cirrhosis and hepatocellular carcinoma. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12612] [Reference Citation Analysis]
10 Zhang G, Lv X, Yang Q, Liu H. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma. BMC Cancer 2022;22:888. [PMID: 35964022 DOI: 10.1186/s12885-022-09987-2] [Reference Citation Analysis]
11 Luo N, Zhong W, Li J, Lu J, Dong R. CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges. Mol Biol Rep 2022. [PMID: 35960410 DOI: 10.1007/s11033-022-07713-6] [Reference Citation Analysis]
12 Liu X, Du S. Letter to the Editor: Inflammation influences the prognosis of hepatocellular carcinoma. Int J Clin Oncol 2022. [PMID: 35962254 DOI: 10.1007/s10147-022-02234-5] [Reference Citation Analysis]
13 Mattos ÂZ, Debes JD, Vogel A, Arrese M, Revelo X, Pase THS, Manica M, Mattos AA. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: Is there a role for immunotherapy? . World J Gastroenterol 2022; 28(28): 3595-3607 [DOI: 10.3748/wjg.v28.i28.3595] [Reference Citation Analysis]
14 Da Fonseca LG, Hashizume PH, de Oliveira IS, Izquierdo-sanchez L, Saud LRDC, Xerfan MP, Alves VAF, de Mello ES, Herman P, Banales JM, Oliveira CP, Carrilho FJ. Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence. Cancers 2022;14:3483. [DOI: 10.3390/cancers14143483] [Reference Citation Analysis]
15 Che L, Du ZB, Wang WH, Wu JS, Han T, Chen YY, Han PY, Lei Z, Chen XX, He Y, Xu L, Lin X, Lin ZN, Lin YC. Intracellular antibody targeting HBx suppresses invasion and metastasis in hepatitis B virus-related hepatocarcinogenesis via protein phosphatase 2A-B56γ-mediated dephosphorylation of protein kinase B. Cell Prolif 2022;:e13304. [PMID: 35811356 DOI: 10.1111/cpr.13304] [Reference Citation Analysis]
16 Jing W, Peng R, Li X, Lv S, Duan Y, Jiang S, Wang F. Study on the Prognostic Values of TTC36 Correlated with Immune Infiltrates and Its Methylation in Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/7267131] [Reference Citation Analysis]
17 Gairing SJ, Schattenberg JM. The unmet need of personalized HCC screening-Lessons learned from the Swedish nationwide registries. United European Gastroenterol J 2022. [PMID: 35567573 DOI: 10.1002/ueg2.12239] [Reference Citation Analysis]
18 Sun CY, Zheng ZL, Chen CW, Lu BW, Liu D. Targeting Gut Microbiota With Natural Polysaccharides: Effective Interventions Against High-Fat Diet-Induced Metabolic Diseases. Front Microbiol 2022;13:859206. [PMID: 35369480 DOI: 10.3389/fmicb.2022.859206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hu X, Zhu H, Chen B, He X, Shen Y, Zhang X, Chen W, Liu X, Xu Y, Xu X. Tubulin Alpha 1b Is Associated with the Immune Cell Infiltration and the Response of HCC Patients to Immunotherapy. Diagnostics 2022;12:858. [DOI: 10.3390/diagnostics12040858] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ryu E, Xia HH, Guo GL, Zhang L. Multivariable-adjusted trends in mortality due to alcoholic liver disease among adults in the United States, from 1999-2017. Am J Transl Res 2022;14:1092-9. [PMID: 35273712] [Reference Citation Analysis]
22 Lombardi R, Piciotti R, Dongiovanni P, Meroni M, Fargion S, Fracanzani AL. PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease. Int J Mol Sci 2022;23:2707. [PMID: 35269846 DOI: 10.3390/ijms23052707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Lyu N, Yi JZ, Zhao M. Immunotherapy in older patients with hepatocellular carcinoma. Eur J Cancer 2021;162:76-98. [PMID: 34954439 DOI: 10.1016/j.ejca.2021.11.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Aydin Y, Koksal AR, Thevenot P, Chava S, Heidari Z, Lin D, Sandow T, Moroz K, Parsi MA, Scott J, Cohen A, Dash S. Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. JHC 2021;Volume 8:1579-96. [DOI: 10.2147/jhc.s327339] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Muller X, Mohkam K, Mabrut JY. Inflammation is king in liver resection for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2021;10:839-41. [PMID: 35004949 DOI: 10.21037/hbsn-21-435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Clavería-Cabello A, Avila MA. HIF2α Activation in NASH: A New Force Pushing Toward HCC. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00239-3. [PMID: 34848185 DOI: 10.1016/j.jcmgh.2021.11.005] [Reference Citation Analysis]